Quikstrip One Step Amphetamine Test
by Drial Consultants, Inc. 510(k)
Active
510(k) K971218
Overview
The Quikstrip One Step Amphetamine Test is an enzyme immunoassay device used to screen urine for the presence of amphetamine and its metabolites. It is designed to detect drug presence rather than monitor specific drug levels.
This device is regulated as a class II medical device under 21 CFR 862.3100 and has received FDA 510(k) clearance. Clinical considerations and professional judgment should be applied to all test results, especially when preliminary positive results are indicated.
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK971218 | Date30 May 1997 | StatusActive |
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not known
- Not covered
United States — FDA 510(k) Active
Recalls
No FDA recalls on record, checked 22 Oct 2026.
Specification
- 510(k) Number
- FDA Product Code
- DKZ
- Device Class
- Class II
- Regulation
- 21 CFR Part 862.3100
- Advisory Committee
- Clinical Toxicology
- FDA Decision
- SESE Substantially Equivalent
Other devices from Drial Consultants, Inc.
Questions
What is the primary purpose of the Quikstrip One Step Amphetamine Test?
This device is intended to screen urine samples for the presence of amphetamine and its metabolites. It is designed to detect the presence of these substances rather than to monitor specific drug levels.
How should clinicians interpret the results from this test?
Clinical considerations and professional judgment should be applied to all test results. This is particularly important when the device indicates a preliminary positive result, as the test is a screening tool.
What is the regulatory classification of this device?
The Quikstrip One Step Amphetamine Test is regulated as a class II medical device under 21 CFR 862.3100 and has received FDA 510(k) clearance.